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Objectives: Escherichia coli is regarded as the most important etiological agent of
urinary tract infections. Fluoroquinolones are routinely used in the treatment of
these infections;however, in recentyears, agrowing rateof resistancetothesedrugs
has been reported globally. The aims of this study were to detect plasmid-mediated
qnrA, qnrB, and qnrS genes among the quinolone-nonsusceptible E. coli isolates
and to investigate their clonal relatedness in Qazvin and Zanjan Provinces, Iran.
Methods:A total of 200 clinical isolates of E. coli were collected from hospitalized
patients. The bacterial isolates were identified through standard laboratory pro-
tocols and further confirmed using API 20E test strips. Antimicrobial susceptibility
was determined by the standard disk diffusion method. Polymerase chain reaction
(PCR) and sequencing were used for detecting qnrA, qnrB, and qnrS genes and the
clonal relatedness of qnr-positive isolates was evaluated by enterobacterial re-
petitive intergenic consensus-PCR (ERIC-PCR) method.
Results: In total, 136 (68%) isolates were nonsusceptible to quinolone compounds,
among which 45 (33.1%) and 71 (52.2%) isolates showed high- and low-level qui-
nolone resistance, respectively. Of the 136 isolates, four (2.9%) isolates were
positive for the qnrS1 gene. The results from ERIC-PCR revealed that two (50%)
cases of qnr-positive isolates were related genetically.
Conclusion: Our study results were indicative of the presence of low frequency of
qnr genes among the clinical isolates of E. coli in Qazvin and Zanjan Provinces,
which emphasizes the need for establishing tactful policies associated with
infection-control measures in our hospital settings.1. Introduction
Clinically, Escherichia coli is an important Gram-
negative bacteria with the potential to cause seriousni).
ase Control and Prevention.
reativecommons.org/licensdisease including urinary tract infections (UTIs), py-
elonephritis, and bacteremia [1]. UTIs, known as the
most common hospital-acquired infections, account for
up to 35% of infections associated with health-carePublished by Elsevier Korea LLC. This is an open access article
es/by-nc-nd/4.0/).
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cause of UTIs [2]. Fluoroquinolones are synthetic and
broad-spectrum antibacterial agents often used for the
treatment of lower UTIs [3]. Inappropriate and unnec-
essary administration of these antibiotics has led to an
increase in the appearance of multidrug-resistant E. coli
isolates, limiting treatment options. Serious health-care-
associated infections caused by these resistant organ-
isms have been associated with considerable morbidity
and mortality [4].
Fluoroquinolones inhibit two bacterial enzymes,
DNA gyrase and topoisomerase IV, both of which play
essential roles in bacterial DNA replication [5]. Resis-
tance to quinolone is often linked to amino acid sub-
stitutions in the quinolone-resistance-determining
regions of DNA gyrase (gyrA and gyrB) and DNA
topoisomerase IV (parC and parE) subunits, leading to
target modification [6]. Decreased outer membrane
permeability through porin changes and overexpression
of naturally occurring efflux systems may also
contribute to chromosomal quinolone resistance [7].
However, recent reports indicate that quinolone resis-
tance can also be mediated by mobile genetic elements
such as plasmids. Plasmid-mediated quinolone resis-
tance is mediated by the genes (qnr) encoding proteins
that belong to the pentapeptide repeat family and protect
DNA gyrase and topoisomerase IV against quinolone
compounds [8]. The three major groups of qnr de-
terminants are qnrA, qnrB, and qnrS [9,10]. The first
plasmid-mediated quinolone-resistance gene (qnrA) was
identified in a clinical strain of Klebsiella pneumoniae
isolated in Alabama in 1998 [11]. The other two de-
terminants of qnr (qnrB and qnrS ) have subsequently
been observed in other enterobacterial species including
E. coli, Enterobacter spp., Salmonella spp., and Kleb-
siella pneumonia [12].
Plasmid-mediated resistance is of growing clinical
concern as they may transfer resistance genes to other
species via horizontal gene transfer, conferring resis-
tance against these antibiotics [13]. Moreover, the
simultaneous presence of extended-spectrum beta-lac-
tamases (ESBLs), AmpC, and qnr genes on the same
plasmid has been well documented and this highlights
the complexity of determinants involved in plasmid-
mediated resistance among the enterobacterial isolates
in medical settings [14]. Obviously, the widespread
appearance of a growing trend associated with the
prevalence of plasmid-mediated resistance among
enterobacterial isolates is undeniable; however, only
limited numbers of studies have been reported from Iran
addressing the prevalence of qnr genes among the
clinical isolates of E. coli. The aim of this study was,
therefore, to investigate the presence of qnr de-
terminants among E. coli isolates collected from a
number of hospitals in two Iranian provincesdZanjan
and Qazvin.2. Materials and methods
2.1. Study design and bacterial isolates
In this cross-sectional study, 200 nonrepetitive E. coli
isolates were obtained from the clinical sample of UTI
patients admitted to hospitals in Zanjan (1 hospital) and
Qazvin (3 hospitals) between July 2014 and December
2015. The organisms were identified by standard labo-
ratory methods and later confirmed using the API 20 E
test strips (bioMe´rieux, Marcy l’Etoile, France). The
isolates were stored at 70C in Trypticase soy broth
containing 20% glycerol and subcultured two times
prior to testing. The mean age of patients was
50.47 18.8 years (range, 13e85 years). There were
153 (76.5%) female and 47 (23.5%) male patients.
2.2. Antimicrobial susceptibility
The KirbyeBauer disk diffusion method was per-
formed according to the Clinical Laboratory Standards
Institute guidelines [15] to detect quinolone-resistance
phenotype using nalidixic acid (10 mg), ciprofloxacin
(5 mg), gatifloxacin (5 mg), norfloxacin (10 mg), levo-
floxacin (5 mg), imipenem (10 mg), and meropenem
(10 mg) disks. If the results of antibiotic-susceptibility
test confirmed the presence of resistance to both cipro-
floxacin and nalidixic acid, the isolates were marked as
high-level quinolone-resistant bacteria, whereas nali-
dixic acid-resistant or intermediate isolates and
ciprofloxacin-susceptible isolates were marked as low-
level quinolone-resistant bacteria [16]. Antibiotic disks
were purchased from Mast Company (Mast Diagnostics
Group Ltd, Merseyside, UK). E. coli American Type
Culture Collection (ATCC) 25922 and Pseudomonas
aeruginosa ATCC 27853 were used as quality-control
strains in antimicrobial susceptibility testing.
2.3. DNA extraction and detection of qnr-
encoding genes
The detection of qnrA, qnrB, and qnrS plasmid-
mediated quinolone-resistance genes was performed
using polymerase chain reaction (PCR) and specific
primers (Table 1) [17]. Plasmid DNA was extracted
using plasmid mini-extraction kit (Bioneer, Daejeon,
South Korea). PCR amplifications were performed in a
thermocycler (Applied Biosystems, USA) as follows:
95C for 5 minutes and 35 cycles of 1 minute at 95C, 1
minute at specific annealing temperature for each primer,
and 1 minute at 72C. A final extension step of 10 mi-
nutes at 72C was performed. Amplification reactions
were prepared in a total volume of 25 mL (24 mL of PCR
master mix plus 1 mL of template DNA) including 5 ng
of genomic DNA, 2.0 U of Taq DNA polymerase (Fer-
mentas, Vilnius, Lithuania), 10mM deoxyribose nucle-
oside triphosphate mix at a final concentration of
0.2mM, 50mMMgCl2 at a final concentration of 1.5mM,
1mM of each primer, and 1 PCR buffer (final
Table 1. Primers used for detection of qnr genes in urinary Escherichia coli isolates.













E. coli qnr genes 309concentration). PCR products were electrophoresed on
1% agarose gel at 100 V and stained with ethidium
bromide solution and finally visualized in gel docu-
mentation system (UVItec Limited, Cambridge, UK).
2.4. Clonal analysis of qnr-positive isolates
All qnr-positive E. coli isolates were tested for
epidemiological relationships using enterobacterial re-
petitive intergenic consensus-PCR (ERIC-PCR) as pre-
viously described by Smith et al [18]. PCR cycling
conditions were as follows: denaturation at 94C for 1
second, annealing at 52C for 10 seconds, and extension
at 72C for 35 seconds for 30 cycles, followed by a final
extension at 72C for 4 minutes. The final products were
electrophoresed on 1.5% agarose gels. Visual compari-
son was employed to examine the fingerprints, and the
patterns varying by two or more bands were classified as
different.
2.5. Statistical analysis
Statistical data analysis was performed for descrip-
tive statistics including frequencies, cross tabulation of
microbiological and clinical features, and demographic
characteristics using the computer software program
SPSS version 16 (SPSS Inc., Chicago, IL, USA).Table 2. Antimicrobial susceptibility of Escherichia coli









Nalidixic acid 65 (32.5) 2 (1) 133 (66.5)
Gatifloxacin 84 (42) e 116 (58)
Levofloxacin 85 (42.5) 3 (1.5) 112 (56)
Ciprofloxacin 88 (44) e 112 (56)
Norfloxacin 89 (44.5) e 111 (55.5)
Imipenem 182 (91) 16 (8) 2 (1)
Meropenem 186 (93) 12 (6) 2 (1)
IZ intermediate; RZ resistant; S Z susceptible.3. Results
3.1. Resistance to quinolone compounds
A total of 200 E. coli isolates were obtained from
patients admitted to internal medicine (82; 41%),
intensive care unit (52; 26%), infectious diseases (49;
24.5%), surgery (11; 5.5%), and neurosurgery (6; 3%)
wards. According to the results of the disk diffusion
method, the highest resistance rate of isolates was
against nalidixic acid (67.5%) and gatifloxacin (58%),
whereas 44.5% and 44% of isolates demonstrated the
highest rate of susceptibility to norfloxacin and cipro-
floxacin, respectively. Overall, 136 (68%) isolates were
nonsusceptible to quinolone compounds used in this
study. High-level quinolone resistance was found in 45
(33.1%) isolates, and 71 (52.2%) bacterial samples
revealed low-level quinolone resistance. In total, 93%and 91% of isolates were sensitive to meropenem and
imipenem, respectively (Table 2).
3.2. Presence of qnr-encoding genes
PCR and sequencing showed that four (2.9%) of the
136 quinolone-nonsusceptible E. coli isolates carried
qnrS1. The qnrA and qnrB genes were not found among
the clinical isolates of this study. As shown in Table 3,
qnrS1-positive isolates were mostly isolated from the
internal medicine wards. Three of four (75%) isolates
showed high quinolone-resistance level.
3.3. Clonal relatedness of qnr-positive isolates
The results obtained by ERIC-PCR were indicative of
the presence of two (50%) qnr-positive E. coli clinical
strains isolated from Zanjan hospital with similar ERIC-
PCR patterns but, as shown in Figure 1, with a genotypic
pattern unrelated to the two isolates collected from
Qazvin hospitals.4. Discussion
UTIs are the commonest type of bacterial infections
and E. coli is the most prevalent cause of UTIs [1].
Quinolones are the most widely used antibacterial
agents in fighting against serious infections caused by E.
coli and other members of Enterobacteriaceae in Iran
[19]. However, plasmid-mediated quinolone resistance
Table 3. Case history and characteristics of the four qnrS1-positive Escherichia coli isolates collected from Qazvin and
Zanjan hospitals.
Isolates City Age (y)/sex Ward
Resistance level to
fluoroquinolone Antibiotic-susceptibility profile ERIC profile
EC 36 Qazvin 32/Female Internal High NAZR, CIPZ R, LEVZ R, NORZ R,
GATZR, IMPZ S, MEMZ S
A
EC 75 Zanjan 70/Female Intensive
care unit
High NAZR, CIPZ R, LEVZ R, NORZ R,
GATZR, IMPZ S, MEMZ S
B
EC 76 Qazvin 42/Male Internal Low NAZR, CIPZ S, LEVZ S, NORZ S,
GATZ S, IMPZ S, MEMZ S
C
EC 127 Zanjan 59/Female Internal High NAZR, CIPZ S, LEVZ S, NORZ S,
GATZ S, IMPZR, MEMZ R
B
CIPZ ciprofloxacin; ERICZ enterobacterial repetitive intergenic consensus; GATZ gatifloxacin; IMPZ imipenem; LEVZ levofloxacin;
MEMZmeropenem; NAZ nalidixic acid; RZ resistant; S Z susceptible.
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E. coil, has led to treatment failures and currently is
becoming a significant public health concern. Plasmid-
mediated resistance to quinolones is being increasingly
reported in studies from Asia, Europe, Australia, and the
United States [20]. However, the number of reports on
prevalence of qnr genes among Iranian enterobacterial
isolates is only limited to few studies.
This study showed a high level of antimicrobial
resistance against quinolone compounds among urinary
E. coli isolates. Overall, 67.5% and 56% of isolates were
either fully resistant or had intermediate resistance to
nalidixic acid and ciprofloxacin, respectively. Our re-
sults were partly similar to the resistance levels reportedFigure 1. Enterobacterial repetitive intergenic consensus-
profiles of four qnr-positive Escherichia coli isolated from
Qazvin and Zanjan hospitals. Lane 1Z 100-bp DNA ladder,
Lanes 2 and 4Z EC 36 and EC 76 (Qazvin hospitals); Lanes 3
and 5Z EC 75 and EC 127 (Zanjan hospital).in two previously conducted studies in Iran. Firoozeh
et al [19] reported that 82.5% and 45% of urinary E. coli
isolates were resistant to nalidixic acid and ciprofloxa-
cin, respectively. In another study from Iran, Khorvash
et al [21] found that 76% and 52% E. coli isolates
associated with nosocomial infection were resistant to
nalidixic acid and ciprofloxacin, respectively. In our
neighboring country, Pakistan, Muhammad et al [22]
showed that 84.2% and 36.5% of E. coli isolated from
UTIs were resistant to nalidixic acid and ciprofloxacin,
respectively. In China, the frequency of ciprofloxacin
resistance among the urinary E. coli isolates was 59.4%
[23]. It seems that unnecessary and widespread admin-
istration of these antibacterial agents is the most
important predisposing factor that could eventually lead
to appearance of resistant bacteria in our hospital set-
tings. Moreover, the resistance rate found in this study
emphasizes the need for a local and national antimi-
crobial resistance surveillance system in bacterial iso-
lates present in our hospital settings.
In this study, meropenem and imipenem showed
high-level susceptibility against E. coli infections.
Currently, the treatment of infections caused by multi-
drug resistant Gram-negative bacteria is achieved by
administration of carbapenems as the drugs of choice;
however, in this study, 9% and 7% of isolates were
either fully resistant or had intermediate susceptibility to
imipenem and meropenem, respectively, a finding that
would have more clinical impact if these strains become
more prevalent in the future.
This study demonstrated a low prevalence rate
(2.9%) of plasmid-mediated quinolone resistance
(qnrS1) among quinolone-nonsusceptible E. coli isolates
in educational hospitals of Qazvin and Zanjan Prov-
inces. We did not find the qnrA and qnrB genes in our
clinical isolates. The frequency of qnr genes in our study
was lower than those found in the two studies previously
conducted in Iran. In a study from Khorramabad (Iran),
Firoozeh et al reported that 14 (12.1%) and nine (7.8%)
nalidixic acid-resistant E. coli isolates were positive for
qnrA and qnrB genes, respectively [19]. In another study
E. coli qnr genes 311from Tehran, Pakzad et al [24] showed that qnrA and
qnrB genes were present in 37.5% and 20.8% of ESBL-
producing E. coli isolates, respectively. Like our study, a
low frequency for qnr gene isolation was also described
by other reports. In Brazil, Pereira et al [25] reported
that only a single E. coli isolate among 144
ciprofloxacin-resistant isolates was positive for qnr
genes. In Singapore, Deepak et al [26] also showed that
1.8% of urinary isolates of E. coli were found to possess
the qnrS gene.
In Denmark, Cavaco et al [27] showed only 1.6% of
nalidixic acid-resistant E. coli isolates as qnr positive. In
France, qnr genes were present in 1.6% of ESBL-
producing E. coli and Klebsiella spp. isolates [28]. In
Canada, only about 1% of ciprofloxacin- and/or
tobramycin-resistant E. coli and Klebsiella spp. isolates
were qnr positive [29]. Nevertheless, the high preva-
lence rate of qnr genes has also been detected in Egypt
where 26.6% of ESBL-producing E. coli isolates were
positive for qnr genes, among which qnrA1-, qnrB1-,
and qnrS1-type genes were detected alone or in com-
bination in 16.6%, 23.3%, and 16.6% isolates, respec-
tively [30]. We previously showed the high appearance
of qnrB1, qnrS1, and qnrB4 genes among the clinical
isolates of K. pneumoniae in Iran [31].
In this study, most qnr-positive isolates showed high-
level resistance. Because qnr genes are responsible for
low-level resistance to quinolones, it can be hypothe-
sized that high-level resistance pattern could be linked
to the presence of other mechanisms such as secondary
changes in DNA gyrase or topoisomerase IV, and porin
or efflux systems, which was not evaluated in our study.
In this work, the ERIC-PCR analysis of two qnr-
positive isolates from Qazvin confirmed that these two
isolates were epidemiologically unrelated; the explana-
tion for this finding may be attributed to the fact that the
clinical isolates from Qazvin were collected from two
different hospitals, whereas those obtained from Zanjan
were collected from the same hospital, resulting in
identical genetic profile.
In conclusion, results of this study revealed the low
prevalence rate of plasmid-mediated quinolone resis-
tance associated with the presence of qnr genes among
the clinical isolates of E. coli in Qazvin and Zanjan
Provinces, Iran. The appearance of quinolone resistance
through this type of mechanism within the Iranian
health-care system could produce serious therapeutic
and epidemiological concerns, which can be overcome
through establishing appropriate infection control mea-
sures as well as comprehensive guidelines on proper
administration of antibacterial in our medical centers.Conflicts of interest
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